New prognostic model predicts survival in advanced prostate cancer

October 21, 2013, Duke University

(Medical Xpress)—For men with advanced prostate cancer that has progressed after taking hormones and undergoing chemotherapy, getting an accurate prognosis is critical to determine the next steps for treatment.

But a good prognostic tool has been lacking in this setting, particularly since a new called cabazitaxel as been approved by the U.S. Food and Drug Administration as another line of treatment.

Now researchers at the Duke Cancer Institute have developed a tool for doctors to forecast the potential survival of individual , enabling them to better and rapidly assess whether to try additional rounds of treatment or seek clinical trials.

The findings are published online in the Journal of the National Cancer Institute.

"Several new treatments have been developed in recent years that prolong life for men with metastatic ," said Susan Halabi, PhD, professor of biostatistics and bioinformatic at Duke and lead author of the study. "As a result, it's increasingly important to provide a clear prognostic picture that can help guide both doctors and patients to the best options."

In their study, Halabi and colleagues developed and validated the new prognostic tool using two different clinical trials of prostate cancer patients whose cancer returned after they had undergone a regimen of docetaxel, the standard first-round chemotherapy that is used after hormone treatments have been ineffective.

The researcher's approach provides an understanding of the complex interactions between the host, the tumor factors and clinical outcomes.

By plugging in 17 variables – including pain intensity, measurable disease, race, age, body mass index and others - the researchers homed in certain key factors that were relevant to overall survival.

Of the 17 variables, nine were determined to be predictive of survival: how a patient's physical performance is rated on a scale of 0-2; the length of time since the first chemotherapy ended; how extensive the disease is; whether the disease has spread to the liver, lungs or other organs; how much pain the patient is experiencing; the duration of hormone use; and levels of hemoglobin, prostate specific antigen and alkaline phosphatase.

Two of those factors had not previously been used in prognostic models - the duration of hormone therapy and the amount of time since the first-round docetaxel treatment.

"Our findings provide a that relies on information tha is routinely collected in clinical practice and should be readily available," Halabi said. "For patients with who are appropriate candidates for second-line chemotherapy, this model can be helpful for guiding care. It could also be used during to assign patients in risk groups based on measurable criteria."

Explore further: Liver metastases and its prognostic significance in men with metastatic prostate cancer

Related Stories

Liver metastases and its prognostic significance in men with metastatic prostate cancer

May 31, 2012
Liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC), according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in ...

Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival

January 12, 2012
Jefferson's Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind ...

Phase 3 trial confirms abiraterone acetate efficacy for patients with advanced prostate cancer

September 17, 2012
Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga) offers a significant survival benefit to patients with castration-resistant prostate cancer, ...

ASCO: anticoagulant use predicts metastatic prostate CA survival

February 19, 2013
(HealthDay)—Anticoagulant use is associated with improved overall survival in men receiving docetaxel chemotherapy for treatment of metastatic castration-resistant prostate cancer (mCRPC), according to research presented ...

Study discovers gene signature that predicts prostate cancer survival

October 10, 2012
Researchers from Mount Sinai School of Medicine have identified a six-gene signature that can be used in a test to predict survival in men with aggressive prostate cancer, according to new research published in the October ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.